Hypertension — thematic synthesis of patient experience¶
Last updated: 2026-09-01
Themes are reported in aggregate, drawn from published qualitative research and evidence syntheses. Every theme below is supported by at least two independent sources. No participant quotations are reproduced; no names or identifying details appear. Method and ethics: README.md. Sources with annotations: sources.md.
T1. The diagnosis is hard to hold on to because nothing hurts¶
Supported by: Malkon 2023 (PMID 38106370); Rahmawati 2018 (PMID 28669227); Shamsi 2017 (PMID 28461866); Johnston 1984 (PMID 6725496)
Understanding of what hypertension is and why it is treated is limited even among people already established on medication (PMID 38106370). Where hypertension goes untreated, patients' own explanations centre on the absence of symptoms and on competing life priorities rather than on refusal (PMID 28669227). Retrospective accounts of the period before diagnosis describe stress and life disruption rather than a sense of illness developing (PMID 28461866). The oldest strand of this literature is the labelling work showing that being told one is hypertensive has measurable effects on work and social function independent of any physiological change (PMID 6725496) — the diagnosis is an event in a life even when the disease is not.
T2. The medication, not the disease, is what is experienced¶
Supported by: Malkon 2023 (PMID 38106370); Tsiantou 2010 (PMID 20859460); Ghai 2024 (PMID 38991671); Kovoor 2024 (PMID 38744907)
Fear of adverse effects is one of the two most consistent findings across settings and decades (PMIDs 38106370, 20859460). Habit-formation research found that experiencing side effects functions as both a barrier and, for some people, a facilitator of routine-building depending on how they are interpreted; frequent prescription changes and polypharmacy disrupted habit formation, while stable daily anchors, planning, pillboxes and visual reminders supported it (PMID 38991671). Participants in a trial of ultra-low-dose quadruple combination therapy gave their own account of what a simplified regimen means to them (PMID 38744907).
T3. Self-monitoring is simultaneously empowering and burdensome¶
Supported by: Natale 2023 (PMID 36840919); Baratta 2022 (PMID 35687380); Strandberg 2023 (PMID 38746569); Grant 2019 (PMID 31262847)
The thematic synthesis of 35 qualitative studies and 872 patients identifies four themes: enabling autonomy and empowerment; providing reassurance and convenience; triggering confusion and stress — anxiety over unfavourable readings, a constant reminder of illness identity, feeling disregarded by clinicians, low confidence interpreting results, uncertainty about targets and frequency, and doubts about device reliability; and financial and operational burden of the device itself (PMID 36840919). Studies of telemonitoring find patients and professionals valuing it along different dimensions (PMIDs 35687380, 38746569), and embedded qualitative work within a self-monitoring trial documents how the technology is actually used in daily life (PMID 31262847). The synthesis's own conclusion is that inadequate knowledge about targets and interpretation, limited device access and psychological burden all limit home monitoring.
T4. Cost and access dominate accounts wherever resources are constrained¶
Supported by: Reddy 2025 (PMID 40285540); Piette 2006 (PMID 16765278); Edward 2021 (PMID 34407820); Gupta 2019 (PMID 30809390); Basu 2022 (PMID 32938210); Najjuma 2020 (PMID 32897274); Oyibo 2025 (PMID 40845429)
Cost-related medication non-adherence remains prevalent among US adults with hypertension (PMID 40285540), and the decision to underuse medication under financial pressure depends on properties of the drug and not only on its price (PMID 16765278). In low- and middle-income settings, patient accounts are dominated by availability, distance, cost and clinic structure — documented independently in Tanzania (PMID 34407820), rural India (PMID 30809390), Delhi (PMID 32938210), Uganda (PMID 32897274) and Nigeria (PMID 40845429). This theme is distinct from T2: it is about whether treatment is obtainable, not about how it feels.
T5. Trust, culture and community shape adherence more than knowledge does¶
Supported by: Abel 2022 (PMID 35171867); Yogarajah 2025 (PMID 40389279); Abdul Wahab 2021 (PMID 34675490); Al-Bayan 2016 (PMID 27733142); Kohrman 2024 (PMID 38723012)
Accounts from Black women in the US emphasise trust in the health system, competing responsibilities and prior experience of care (PMID 35171867); parallel themes appear among Black African and Black Caribbean residents in south-east London (PMID 40389279). Ethnographic work documents religiosity and spirituality as influences on medication-taking (PMID 34675490). Neighbourhood conditions — safety, food environment, chronic stress — feature directly in low-income Black women's explanations of their own hypertension (PMID 27733142). Post-trial interviews with participants, barbers and pharmacists in a barbershop-based programme explain why care delivered inside an existing trusted setting achieved what clinic-based care had not (PMID 38723012).
T6. Physical activity is wanted but not resourced¶
Supported by: Li 2024 (PMID 39407187); M Yatim 2019 (PMID 31207425)
A synthesis of 17 qualitative studies mapped physical-activity experience onto capability (age, comorbidity, knowledge and skills), opportunity (time, environment, resources, social support) and motivation (self-efficacy, pursuit of health, prior experience) (PMID 39407187). Work on self-management practices reaches compatible conclusions about the role of resources and support (PMID 31207425). The pattern is that most identified barriers are environmental rather than motivational — consistent with the durability asymmetry documented in the trial literature, where environment-level interventions outlast behaviour-level ones.
T7. Older people and their clinicians are each waiting for the other to raise deprescribing¶
Supported by: van Bussel 2019 (PMID 31427342); Ghai 2024 (PMID 38991671)
In interviews with community-dwelling people aged 74–93 with hypertension and no prior cardiovascular disease, participants rarely initiated a conversation about hypertension management despite having concerns; reasons included low priority, reliance on and trust in the general practitioner, and anticipated regret about reducing medication for fear of a vascular event. What they wanted to discuss was tailoring, deprescribing, side-effect reduction and greater transparency about how much treatment actually delivers. The authors identify a mutual silence, since clinicians are also known to be reluctant to raise the subject (PMID 31427342). The polypharmacy and regimen-change themes in habit-formation research are compatible (PMID 38991671). This has direct clinical weight given that supervised deprescribing was feasible over 12 weeks in a randomised trial and that treatment-related harm concentrates in frailty.
T8. Care is easier to accept when it is delivered where people already are¶
Supported by: Kohrman 2024 (PMID 38723012); Baratta 2022 (PMID 35687380); Cairns 2020 (PMID 32517785)
Interviews with participants in a barbershop-based programme describe a setting where health conversation was already normal and the pharmacist came to them (PMID 38723012). Implementation work on a postpartum self-management intervention describes what made a home-based, physician-supported regimen workable for new mothers (PMID 32517785). Telemonitoring studies describe a similar logic from a different direction — reducing the number of clinic visits was itself valued (PMID 35687380).
T9. Patients want to know what treatment actually buys them¶
Supported by: Malkon 2023 (PMID 38106370); van Bussel 2019 (PMID 31427342); Natale 2023 (PMID 36840919)
Across studies, the request that recurs is not for more information in general but for decision-relevant information: what the number means, what the benefit is in terms they can weigh, and what the alternatives are. Patients report short appointments, prescribing without conversation and limited individualisation (PMID 38106370); older people expect clinicians to be more transparent about treatment effect (PMID 31427342); and self-monitoring users report not knowing what target they are aiming at or how to respond to a reading (PMID 36840919). A 210-person randomised trial did provide individualised 10-year risk and absolute risk-reduction counselling; it did not significantly change medication use (OR 1.35, 95% CI 0.77–2.36) or adherence (OR 1.15, 0.67–2.00) (PMID 31473598). The positively stated evidence gap at the 2026-09-01 audit is an adequately powered trial that isolates absolute versus relative framing rather than comparing a multicomponent counselling package with general counselling.
Themes recorded but not yet meeting the two-source threshold¶
These are noted so that a later sweep can confirm or drop them; they are not treated as established themes:
- Competing treatment priorities when hypertension is managed alongside another chronic condition with a more salient identity — observed in HIV care (PMID 42239779) and, differently, in pandemic-disrupted chronic care (PMID 34145019).
- The clinician-side counterpart of T7 — clinicians' own reluctance to raise deprescribing — is asserted in PMID 31427342 but is not directly evidenced by a second qualitative study in this collection.
- Concordance as a longitudinal process rather than a state, described in older primary-care work (PMID 17487567), awaits a contemporary replication in this collection.